The review team, led by researchers spanning institutions in Saudi Arabia, Nigeria, China, and Egypt, searched PubMed, PsycINFO, Scopus, and ClinicalTrials.gov on 23 February 2026, following PRISMA-ScR reporting guidelines and a Population, Concept, and Context framework. Uniquely, the authors deliberately distinguished peer-reviewed clinical studies from trial registrations, regulatory documents, and company communications, treating the latter as contextual or preliminary evidence rather than established clinical findings. This approach matters in a field where commercial development is moving faster than the published literature, and where preliminary claims can otherwise blur into perceived clinical fact.

The most mature evidence comes from two multicenter phase 3 randomized trials of MDMA-assisted therapy for PTSD. In the first, 90 participants with severe PTSD who received MDMA alongside manualized psychotherapy showed significantly greater reductions in clinician-rated symptoms on the CAPS-5 scale than those receiving placebo with the same psychotherapy, with a between-group effect size of approximately 0.91. The second trial replicated the finding in 104 participants with moderate to severe PTSD: the least-squares mean change in CAPS-5 score was −23.7 points with MDMA-assisted therapy versus −14.8 with placebo plus therapy, a difference the authors characterized as large.

Functional impairment, measured with the Sheehan Disability Scale, also improved more in the MDMA groups. Seven severe treatment-emergent adverse events were reported across both treatment arms, with no serious treatment-emergent adverse events or deaths during the trials. Psilocybin evidence spans both major depressive disorder and treatment-resistant depression.

In a phase 2 randomized trial of 104 adults with major depressive disorder, a single 25-milligram dose of psilocybin administered with psychological support produced rapid reductions in depressive symptoms that persisted through six weeks of follow-up. A larger randomized trial in 233 participants with treatment-resistant depression compared single doses of 1, 10, or 25 milligrams, and found that the 25-milligram group improved significantly more than the 1-milligram group at three weeks, providing evidence of a dose-related difference in the primary efficacy outcome. Follow-up analyses from development programs suggested persistence of benefit beyond primary endpoints, though these were based on subsets and follow-up cohorts rather than the randomized primary analyses themselves.

Not all psilocybin findings were uniformly positive. A phase 2 trial comparing psilocybin with the standard antidepressant escitalopram in 59 participants with major depressive disorder did not reach statistical significance on its prespecified primary outcome, the QIDS-SR-16, at six weeks, although several secondary outcomes favored psilocybin. The review authors emphasize that such differences across comparators, outcome measures, follow-up periods, and populations mean the psilocybin literature should not be described as uniformly favorable.

Beyond the two flagship areas, the review identified a phase 2b randomized, double-blind, placebo-controlled trial of MM120, a lysergide formulation, in 198 adults with moderate to severe generalized anxiety disorder. Participants received placebo or doses of 25, 50, 100, or 200 micrograms, and the study found a significant dose-related reduction in anxiety symptoms, with the 100-microgram dose producing substantial improvement at the primary four-week endpoint. By contrast, evidence for DMT-assisted therapy, including investigational formulations such as SPL026, consisted largely of early-phase research, trial registrations, and industry communications.

The review also flagged a citation discrepancy: a previously cited publication was found to concern an anti-tau antibody rather than a psychedelic intervention, and was excluded from the DMT synthesis. Perhaps the review's most consequential methodological finding concerns blinding. The pronounced subjective effects of psychedelics make conventional placebo-controlled designs difficult to maintain, since participants and therapists can often correctly infer who received the active drug.

This functional unblinding opens the door to expectancy effects that may inflate both self-reported and clinician-rated outcomes, and public enthusiasm for psychedelic treatments may further shape participants' experiences. The U.S. Food and Drug Administration's 2023 draft guidance on psychedelic drug development explicitly highlighted these challenges, calling for trial designs that can separate the contributions of the drug, the psychotherapy, the treatment context, and expectancy. Proposed remedies include more credible active comparators and prospective measurement of treatment-guessing, though no comparator fully reproduces the subjective and physiological profile of a psychedelic experience.

The psychotherapeutic component of these treatments emerged as a central but under-studied variable. Nearly all contemporary protocols combine preparatory sessions, supervised drug administration, and post-session integration, yet the content, intensity, duration, and theoretical orientation of the psychotherapy vary considerably across studies. MDMA-assisted therapy has used a relatively standardized model emphasizing participant-led emotional processing, whereas classic psychedelic studies show much greater variation.

The review concludes that the available evidence does not establish that any single psychotherapeutic model or therapist-related factor is necessary or sufficient for clinical improvement, and that the relative contributions of pharmacological effects, therapeutic processes, expectancy, and environment remain incompletely characterized. Mechanistic literature points to serotonin 5-HT2A receptor signaling, altered large-scale brain-network activity, increased cognitive flexibility, and changes in emotional and self-related processing, but associations between the intensity of acute psychedelic experiences and later improvement do not establish that the experience itself causes therapeutic change. Safety findings across the reviewed trials were generally consistent: headache, nausea, dizziness, transient anxiety, and temporary cardiovascular changes such as elevated blood pressure were the most commonly reported acute adverse events, with frequency and severity varying by compound, dose, population, and design.

However, the authors caution that these profiles reflect carefully screened participants, supervised administration, and structured monitoring, and cannot be extrapolated to broader populations or less controlled settings. Follow-up periods varied substantially, trials excluded individuals considered at elevated psychiatric or medical risk, and the evidence was insufficient to rule out longer-term psychiatric or cardiovascular harms. Challenging psychological experiences, including fear and perceptual disturbances, occurred even under controlled conditions; while some authors propose that well-supported difficult experiences may contribute to therapy, the review treats this as a provisional hypothesis rather than established fact.

The ethical and regulatory dimensions of the field receive equally pointed attention. Informed consent is complicated by the altered states of consciousness that psychedelics induce, during which participants may experience heightened suggestibility and vulnerability to interpersonal influence, raising questions about therapist competence, professional boundaries, and the ethical management of touch. Cultural considerations, including appropriate engagement with Indigenous knowledge, and equity concerns about cost, therapist availability, geographic access, and reimbursement were also identified as barriers to fair implementation.

The review further situates recent regulatory and research-integrity events within the evidence landscape: in 2024 the FDA issued a Complete Response Letter regarding the MDMA-assisted therapy application for PTSD, requesting an updated safety assessment, and three phase 2 MDMA publications were retracted following undisclosed protocol violations at a study site. Meanwhile, sponsor-reported phase 3 results for COMP360 psilocybin in treatment-resistant depression showed a statistically significant 6-week difference of −3.6 points in MADRS change between the 25-milligram and placebo groups, pending full peer-reviewed publication. The review's overarching conclusion is that psychedelic-assisted therapy is neither a uniform intervention nor a settled one: future research must move beyond asking whether these treatments produce change to determining how, for whom, and under what therapeutic conditions, with standardized reporting of psychotherapy, rigorous blinding assessment, long-term safety monitoring, and robust ethical frameworks guiding the path toward clinical implementation.

Subject of Research: Scoping review of clinical evidence, mechanisms, safety, and ethics of psychedelic-assisted psychotherapy with psilocybin, MDMA, LSD, and DMT from 2020 to 2025

Article Title: Psychedelic assisted psychotherapy (2020–2025): a scoping review of clinical evidence, mechanisms, safety, and ethics

Article References: Abdullahi, N. M., Menhas, R., Nasir, P. O., Elbqry, M. G., Elmansy, F. M., Al-Ahdal, S. A., Alshmimry, A. H., Arafat, A. E. A., Elgazzar, S. E., & Ashmieg, F. S. O. (2026). Psychedelic assisted psychotherapy (2020–2025): a scoping review of clinical evidence, mechanisms, safety, and ethics. Frontiers in Psychology, 17, 1820860. https://doi.org/10.3389/fpsyg.2026.1820860

Image Credits: AI Generated

DOI: 10.3389/fpsyg.2026.1820860

Keywords: psychedelic-assisted therapy, psilocybin, MDMA, LSD, DMT, PTSD, treatment-resistant depression, generalized anxiety disorder, blinding and expectancy, psychotherapy integration, clinical trial methodology, ethics and equity